Figure 1 illustrates the inhibition of B16 melanoma tumor growth *in vivo* by a combination of VEGFR and PDGFR tyrosine kinase inhibitors.

- **Panel a (Western Blots):** Shows PDGFR $\beta$  phosphorylation (IB: pTyr, top) and total PDGFR $\beta$  (IB: PDGFR $\beta$ , bottom) in PAE/PDGFR $\beta$  cells. The left panel shows stimulation with conditioned media from B16/mock clone or B16/PDGF-BB clone, compared to PBS and PDGF-BB 50 ng/ml. The right panel shows stimulation with PBS, B16/PDGF-BB clone conditioned media, or increasing amounts of PDGF-BB (0.1, 0.5, 5 ng/ml). Molecular weight markers (MW  $\times 10^{-3}$ ) are indicated at 200 kDa.
- **Panel b (Cell Growth):** Shows B16/PDGF-BB cell number (log scale) over time (days) in the presence of vehicle ( $\diamond$ ), 3  $\mu$ M STI571 ( $\blacksquare$ ), 1  $\mu$ M PTK787 ( $\blacktriangle$ ), or 3  $\mu$ M STI571 and 1  $\mu$ M PTK787 ( $\bullet$ ).
- **Panel c (Tumor Growth B16/mock):** Shows tumor volume ( $mm^3$ ) over time (days) for mice bearing B16/mock tumors (n=5 to 7). Treatments include vehicle ( $\diamond$ ), STI571 (100 mg/kg/day,  $\blacksquare$ ), PTK787 (25 mg/kg/day,  $\blacktriangle$ ), or combination (STI571 100 mg/kg/day + PTK787 25 mg/kg/day,  $\circ$ ).
- **Panel d (Tumor Growth B16/PDGF-BB):** Shows tumor volume ( $mm^3$ ) over time (days) for mice bearing B16/PDGF-BB tumors (n=7 to 9). Treatments are the same as in (c). Significance markers (\*,  $\S$ , #) are shown at day 8.
- **Panel e (Inhibition of PDGFR $\beta$  phosphorylation in tumors):** Western blot analysis of PDGFR $\beta$  phosphorylation (IB: pTyr, top) and total PDGFR $\beta$  (IB: PDGFR $\beta$ , bottom) from Sis-NIH3T3 tumor lysates treated with various inhibitors. Lanes: C (control, Rabbit IgG), Veh (vehicle, lanes 2 and 3), STI/PTK combination (lanes 4 and 5), PTK (lanes 6 and 7), STI 100 (lanes 8 and 9), STI 200 (lanes 10 and 11). Relative phosphorylation values are quantified below the blot.

![](_page_0_Figure_2.jpeg)

**FIGURE 1** â€“ Combination of VEGFR and PDGFR tyrosine kinase inhibitors inhibits B16 melanoma tumor growth *in vivo*. (a) Subconfluent cultures of PAE/PDGFR $\beta$  cells were stimulated with conditioned media from B16/mock or B16/PDGF-BB cells for 1 hr on ice (left panels). Alternatively, PAE/PDGFR $\beta$  cells were incubated for 5 min at  $37^{\circ}\text{C}$  with conditioned medium or increasing amounts of PDGF-BB (right panels). PDGFR $\beta$  phosphorylation was analyzed by PDGFR $\beta$  and phospho-tyrosine (pTyr) immunoblotting of wheat germ agglutinin adsorbed fractions of cell lysates. (b) B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle ( $\diamond$ ), 3  $\mu\text{M}$  STI571 ( $\blacksquare$ ), 1  $\mu\text{M}$  PTK787 ( $\blacktriangle$ ) or 3  $\mu\text{M}$  STI571 and 1  $\mu\text{M}$  PTK787 ( $\bullet$ ). B16/mock (c) or B16/PDGF-BB (d) cells were inoculated subcutaneously to C57BL/6J mice. When the tumor volume reached 20  $\text{mm}^3$ , mice received either p.o. gavage of vehicle ( $\diamond$ ), 100 mg/kg/day STI571 ( $\blacksquare$ ), 25 mg/kg/day PTK787 ( $\blacktriangle$ ) or 100 mg/kg/day STI571 and 25 mg/kg/day PTK787 ( $\circ$ ). Treatment was given for 13 days for mice bearing B16/mock tumors (c) and 8 days for mice bearing B16/PDGF-BB tumors (d). Tumor volumes, determined by palpation were followed over time. Results are presented as mean and S.E.M. Statistical significance was evaluated using a one-way ANOVA followed by *post hoc* analysis applying the Duncan adjustment. Significance is shown for the last day of treatment: \*,  $p < 0.05$  compared to vehicle treatment;  $\S$ ,  $p < 0.05$  compared to PTK787 treatment; #,  $p < 0.05$  compared to STI571 treatment. (e) Sis-NIH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/STI571 (25 mg/100 mg/kg/day; lanes 4 and 5), PTK787 (25 mg/kg/day, lanes 6 and 7), STI571 (100 mg/kg/day, lanes 8 and 9) or STI571 (200 mg/kg/day, lanes 10 and 11). PDGFR $\beta$  was immunoprecipitated from 15 mg tumor lysate, and receptor phosphorylation was analyzed by PDGFR $\beta$  and phospho-tyrosine (pTyr) immunoblotting. Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1). The ratio between the densitometric analysis of the phosphotyrosine band and the upper, mature PDGFR $\beta$  band were compared to the first vehicle-treated tumor to obtain the relative receptor phosphorylation.

## Results

### *In vitro characterization of a B16F10 melanoma clone which produces PDGF-BB*

A B16 melanoma cell line producing PDGF-BB (B16/PDGF-BB) was previously established. $^{26}$  This cell line was used to isolate a clone with robust PDGF-BB production that was selected for further experiments. As shown in Figure 1a (left panels), conditioned medium from the selected B16/PDGF-BB clone, but not from a mock-transfected clone (B16/mock), induced strong PDGFR $\beta$  phosphorylation in porcine aortic endothelial cells

transfected with the PDGFR $\beta$  (PAE/PDGFR $\beta$ ), indicating production of a large amount of PDGF-BB. The amount of PDGF-BB released into the conditioned medium was estimated by incubating PAE/PDGFR $\beta$  cells with either conditioned medium or increasing amounts of PDGF-BB. After 2 days, the B16/PDGF-BB cells had released an amount of PDGF into the medium that was in excess of 0.5 ng/ml PDGF-BB (Fig. 1a, right panels). It should be noted that PDGF-BB sticks to both cells and plastic, so this amount is likely to represent underestimation of the production of PDGF-BB.